AI Article Synopsis
- Rotaviruses are the leading cause of severe gastroenteritis and diarrheal deaths in children, especially in developing nations.
- Current vaccines like Rotarix and RotaTeq significantly lower rates of rotaviral gastroenteritis and related hospital visits.
- The ongoing global challenge posed by rotavirus diseases fuels continuous vaccine research and highlights the importance of assessing vaccine effectiveness in different countries.
Article Abstract
Among children, rotaviruses are the most common cause of severe gastroenteritis worldwide and of diarrheal deaths in developing countries. Current vaccines (e.g., Rotarix, GlaxoSmithKline Biologicals; RotaTeq, Merck and Company) effectively reduce rotaviral gastroenteritis, emergency department visits, and hospitalizations. The tremendous burden of rotavirus-related diarrhea in children across the world continues to drive the remarkable pace of vaccine development. This review assesses the global epidemiological and economic burden of rotavirus diseases, summarizes the relevant principles of the development of rotavirus vaccines, and presents data on the efficacy and effectiveness of currently licensed vaccines in both developed and developing countries.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jfma.2011.09.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!